These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7281940)

  • 41. Nonalcoholic steatohepatitis--a histological perspective.
    Sakhuja P; Malhotra V
    Indian J Pathol Microbiol; 2006 Apr; 49(2):163-72. PubMed ID: 16933708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats.
    Qin R; Zhang J; Li C; Zhang X; Xiong A; Huang F; Yin Z; Li K; Qin W; Chen M; Zhang S; Liang L; Zhang H; Nie H; Ye W
    Arch Pharm Res; 2012 Jul; 35(7):1241-50. PubMed ID: 22864747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical aspects and morphology of fatty dystrophy of the liver].
    Bondar' ZA; Podymova SD; Burchakova GI
    Klin Med (Mosk); 1970 Aug; 48(8):104-12. PubMed ID: 5476031
    [No Abstract]   [Full Text] [Related]  

  • 44. Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy.
    Mennesson N; Dumortier J; Hervieu V; Milot L; Guillaud O; Scoazec JY; Pilleul F
    J Comput Assist Tomogr; 2009; 33(5):672-7. PubMed ID: 19820490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Not all models of fatty liver are created equal: understanding mechanisms of steatosis development is important.
    Larter CZ
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1353-4. PubMed ID: 17716338
    [No Abstract]   [Full Text] [Related]  

  • 46. Fatty liver. Chemical shift phase-difference and suppression magnetic resonance imaging techniques in animals, phantoms, and humans.
    Mitchell DG; Kim I; Chang TS; Vinitski S; Consigny PM; Saponaro SA; Ehrlich SM; Rifkin MD; Rubin R
    Invest Radiol; 1991 Dec; 26(12):1041-52. PubMed ID: 1765436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Alcoholic hepatic steatosis; epidemiology, pathogenesis, clinical aspects and treatment].
    Barbu N; Banciu T; Bartha P; Turcu LS
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1982; 34(4):303-11. PubMed ID: 6131512
    [No Abstract]   [Full Text] [Related]  

  • 48. [Non-alcoholic steatohepatitis].
    Moreno Sánchez D
    An Med Interna; 1989 Feb; 6(2):100-3. PubMed ID: 2491061
    [No Abstract]   [Full Text] [Related]  

  • 49. [An investigation of the relationship between heavy drinking and alcoholic fatty liver in the Xinjiang minority ethnic group].
    Yang RQ; Zhang XH; Tian XM; Guan CY; Shi L; Wang JG; Meng XY; Na ZM; Sha JD; Wang BY
    Zhonghua Gan Zang Bing Za Zhi; 2005 Nov; 13(11):849-51. PubMed ID: 16313736
    [No Abstract]   [Full Text] [Related]  

  • 50. Fatty liver and elevated transaminases with heterozygous apolipoprotein B deficiency.
    Shah SS; Desai HG
    J Assoc Physicians India; 2001 Feb; 49():284-5. PubMed ID: 11225149
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Diabetes and non-alcoholic fatty liver disease].
    Gariani K; Philippe J; Jornayvaz FR
    Rev Med Suisse; 2012 Jun; 8(344):1211-4. PubMed ID: 22730617
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New insights in the pathogenesis of non-alcoholic fatty liver disease.
    Gaemers IC; Groen AK
    Curr Opin Lipidol; 2006 Jun; 17(3):268-73. PubMed ID: 16680031
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comparative studies on fatty liver of various etiology and stage with reference to clinical aspects and functional diagnosis].
    Weise J; Rösch D
    Acta Hepatosplenol; 1971; 18(2):104-19. PubMed ID: 4101558
    [No Abstract]   [Full Text] [Related]  

  • 54. [Alcoholic and non-alcoholic fatty liver hepatitis. When is abstaining from alcohol enough, when do steroids help?].
    Berghaus TM; Beuers U
    MMW Fortschr Med; 2001 Jul; 143(26-27):28-32. PubMed ID: 11481912
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early-phase alcoholic liver disease: an update on animal models, pathology, and pathogenesis.
    Ramaiah S; Rivera C; Arteel G
    Int J Toxicol; 2004; 23(4):217-31. PubMed ID: 15371166
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment of non-alcoholic fatty liver disease].
    Koek GH
    Ned Tijdschr Geneeskd; 2011; 155():A3181. PubMed ID: 21649947
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical diagnosis of alcoholic fatty liver.
    Devenyi P; Rutherdale J; Sereny G; Olin JS
    Am J Gastroenterol; 1970 Dec; 54(6):597-602. PubMed ID: 5504217
    [No Abstract]   [Full Text] [Related]  

  • 58. [Alcoholic fatty liver].
    Vidos I; Katona A; Schaff Z; Lapis K
    Orv Hetil; 1980 May; 121(21):1239-42. PubMed ID: 7422306
    [No Abstract]   [Full Text] [Related]  

  • 59. [Serum immunoglobulin E levels in patient with fatty liver, whether associated with alcohol consumption or not].
    Medina-Santander CE; Morales-Gómez M; Olivares-Romero GJ
    Invest Clin; 2001 Dec; 42(4):241-53. PubMed ID: 11787269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Liver steatosis. I: Macrovesicular steatosis].
    Causse X; Gargot D; Michenet P
    Gastroenterol Clin Biol; 1995 Jan; 19(1):58-65. PubMed ID: 7720992
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.